Elena Monterroso-Armenteros
Oncology R&D, AstraZeneca
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 06, 2026
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.
Journal: The New England journal of medicine
Published: October 17, 2025
A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.
Journal: Future oncology (London, England)
Published: March 07, 2025
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 05, 2024
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 02, 2023
Preclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47phox-Deficient Chronic Granulomatous Disease.
Journal: Human gene therapy
Published: March 20, 2021
The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.
Journal: Leukemia
Published: March 13, 2019
HMGA2 functions as a competing endogenous RNA to promote lung cancer progression.
Journal: Nature
Published: February 05, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026